Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Acquired by Quantbot Technologies LP

Quantbot Technologies LP lifted its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 77.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 114,318 shares of the company's stock after purchasing an additional 49,742 shares during the period. Quantbot Technologies LP owned 0.06% of Cellebrite DI worth $1,925,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CLBT. FMR LLC grew its holdings in Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company's stock valued at $94,586,000 after buying an additional 3,239,307 shares in the last quarter. Telemark Asset Management LLC purchased a new stake in shares of Cellebrite DI in the third quarter valued at about $6,736,000. Advisors Asset Management Inc. increased its position in Cellebrite DI by 130.5% during the third quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company's stock worth $52,000 after purchasing an additional 1,742 shares during the last quarter. Empowered Funds LLC purchased a new position in Cellebrite DI during the third quarter worth about $2,002,000. Finally, MQS Management LLC acquired a new position in Cellebrite DI in the 3rd quarter valued at about $294,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Trading Up 1.5 %

NASDAQ:CLBT traded up $0.29 during midday trading on Friday, reaching $20.18. The company had a trading volume of 1,052,063 shares, compared to its average volume of 1,187,556. The stock's fifty day simple moving average is $18.17 and its 200-day simple moving average is $15.07. Cellebrite DI Ltd. has a 12-month low of $7.91 and a 12-month high of $21.00.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. During the same period in the previous year, the company posted $0.09 earnings per share. The business's revenue for the quarter was up 27.0% on a year-over-year basis. Sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CLBT shares. Needham & Company LLC raised their price target on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. TD Cowen raised their target price on Cellebrite DI from $20.00 to $23.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Bank of America upped their price target on Cellebrite DI from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 16th. JPMorgan Chase & Co. raised their price objective on Cellebrite DI from $21.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Finally, Lake Street Capital upped their target price on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $20.29.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.